Is sparsentan/sparsentan necessary for long-term use? Risks of discontinuation and recommended treatment duration

Sparsentan is a new type of therapeutic drug mainly used to treat chronic kidney disease, especially primary immunoglobulin A nephropathy (IgAN) and FSGS (focal segmental tubulosclerosis). As a dual-action drug, sparsentan combines the mechanisms of action of an angiotensin receptor antagonist and an endothelin A receptor antagonist to help reduce kidney inflammation, fibrosis progression, and reduce proteinuria.

As to the question of whether sparsentin needs to be taken long-term, the answer is usually yes. SinceIgA nephropathy and FSGS are long-term and progressive diseases, patients usually require long-term drug treatment to control the progression of the disease. Sparsentane helps alleviate symptoms and improve patients' long-term prognosis by slowing kidney damage and reducing proteinuria during treatment. Therefore, doctors usually recommend that patients continue to take sparsentane after the disease is under control to maintain the effect and avoid recurrence of the disease.

However, there are risks that may arise after stopping the drug. Since sparsentan acts by inhibiting renal fibrosis and reducing proteinuria, discontinuation of the drug may cause a rebound in the condition, a re-increase in proteinuria levels, and even accelerate the deterioration of renal function. Especially when the disease is more severe or the patient has a longer course of disease, stopping the drug may increase the burden on the kidneys and cause greater damage. Therefore, spaxentan is not a short-term treatment, but a long-term treatment.

Recommendations for treatment courses usually need to be determined based on the individual condition and the doctor’s evaluation. Generally speaking, the course of treatment for IgA nephropathy or FSGS does not have a fixed period, but is adjusted according to the patient's condition changes, treatment effects and side effects. During the initial stages of treatment, doctors may frequently monitor patients' proteinuria levels and kidney function to assess efficacy and side effects. During the treatment process, patients need to follow the doctor's recommendations and undergo regular examinations to ensure that drug use is effectively controlled.

Reference materials:https://www.sparsentan.com/